Induced pluripotent stem cells as custom therapeutics for retinal repair: Progress and rationale

- We review efforts to produce retinal lineage cells from iPS cells.
- We discuss the potential roles of human iPS cells in the treatment of retinal disease.
- The challenges of using human iPS cells in transplantation are reviewed.
- We outline the steps needed to create clinical grade iPS cell therapeutics.

Human pluripotent stem cells have made a remarkable impact on science, technology and medicine by providing a potentially unlimited source of human cells for basic research and clinical applications. In recent years, knowledge gained from the study of human embryonic stem cells and mammalian somatic cell reprogramming has led to the routine production of human induced pluripotent stem cells (hiPSCs) in laboratories worldwide. hiPSCs show promise for use in transplantation, high throughput drug screening, “disease-in-a-dish” modeling, disease gene discovery, and gene therapy testing. This review will focus on the first application, beginning with a discussion of methods for producing retinal lineage cells that are lost in inherited and acquired forms of retinal degenerative disease. The selection of appropriate hiPSC-derived donor cell type(s) for transplantation will be discussed, as will the caveats and prerequisite steps to formulating a clinical Good Manufacturing Practice (cGMP) product for clinical trials.

478